Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634945 | 0.89 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL5633525 | 0.87 | KCNH2 (0.82) | KCNH2 | |
| SCHEMBL5633233 | 0.84 | KCNH2 (0.76) | KCNH2 | |
| SCHEMBL5635444 | 0.84 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL14476192 | 0.82 | KCNH2 (0.73) | KCNH2 | |
| SCHEMBL5026294 | 0.78 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL5633170 | 0.76 | KCNH2 (1.00) | KCNH2CCR2 | |
| SCHEMBL5634775 | 0.75 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL5633512 | 0.74 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL5634038 | 0.73 | KCNH2 (1.00) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244758-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-07-17 | — | — | US | claimed |
| US-20050014748-A1 | N-type calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-01-20 | — | — | US | claimed |
| US-7244758-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014748-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1I | KCNH2 33/4885CCR2 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.